试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-23
LYT-100 in Patients With BCRL
编号:NCT04243837登记状态:提前终止企业 / 申办者:PureTech
药物 / 成分:LYT-100 BCRL、Placebo BCRL
登记的停止原因(原文):Primary objective/endpoint has been established, will not pursue development of the disease indication further
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-23
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
编号:NCT04633148登记状态:提前终止企业 / 申办者:AvenCell Europe GmbH
药物 / 成分:Cyclophosphamide (Non-IMP)、Fludarabine (Non-IMP)、UniCAR02-T-pPSMA、UniCAR02-T (IMP)
登记的停止原因(原文):Although IMP has been well tolerated, biological activity was very limited. The sponsor concluded that continued development of IMP would be unlikely to result in meaningful clinical benefit for patients with prostate cancer.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-23
Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
编号:NCT05524857登记状态:提前终止企业 / 申办者:Joseph Jurcic
药物 / 成分:Fedratinib Oral Capsule 300 mg、Decitabine 20 mg/m2、Fedratinib Oral Capsule 400 mg
登记的停止原因(原文):Closed by Sponsor
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-22
Phase II, Dose Finding Study of GTx-758
编号:NCT01393119登记状态:提前终止企业 / 申办者:GTx
药物 / 成分:GTx-758
登记的停止原因(原文):FDA Clinical Hold
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-22
Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
编号:NCT01751802登记状态:提前终止企业 / 申办者:Emalex Biosciences Inc.
药物 / 成分:Ecopipam、Placebo
登记的停止原因(原文):Study terminated for commercial reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-22
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
编号:NCT02954991登记状态:提前终止企业 / 申办者:Mirati Therapeutics Inc.
药物 / 成分:Glesatinib、Sitravatinib、Mocetinostat、Nivolumab
登记的停止原因(原文):This study was terminated as a result of Sponsor portfolio reprioritization.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-22
P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
编号:NCT03119012登记状态:提前终止企业 / 申办者:Samsung Medical Center
药物 / 成分:Clopidogrel、Ticagrelor、Aspirin
登记的停止原因(原文):cannot use bioabsorbable scaffold
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-22
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
编号:NCT04200352登记状态:提前终止企业 / 申办者:Teva Branded Pharmaceutical Products R&D, Inc.
药物 / 成分:TEV-50717
登记的停止原因(原文):Failure of TV50717-CNS-30080 (parent study) to meet the primary efficacy endpoint
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-22
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
编号:NCT05441826登记状态:提前终止企业 / 申办者:Tenet Medicines
药物 / 成分:VB119
登记的停止原因(原文):Sponsor change
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-19
Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
编号:NCT02085304登记状态:提前终止企业 / 申办者:St. Joseph's Hospital and Medical Center, Phoenix
药物 / 成分:Gross total resection and Gliadel(R) wafers implanted、GammaKnife(R) stereotactic Radiosurgery、Standard fractionated radiation therapy、Temozolomide
登记的停止原因(原文):met stopping rules for futility
查看官方原始记录 ↗